BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021

Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) will report its first quarter 2021 financial results on May 20, 2021, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss these results and provide operational updates. BrainsWay is known for its advanced neurostimulation treatments, holding three FDA-cleared indications for mental health disorders including major depressive disorder. The company aims to expand awareness and access to its Deep Transcranial Magnetic Stimulation technology worldwide.

Positive

• BrainsWay holds three FDA-cleared indications for mental health disorders.
• Commitment to expanding global awareness and access to Deep TMS technology.

Negative

• None.

CRESSKILL, N.J. and JERUSALEM, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its first quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets on Thursday, May 20, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Thursday, May 20, 2021
Time:	8:30 AM Eastern Time
United States:	877-407-3982
Israel:	1 809 406 247
International:	201-493-6780
Conference ID:	13719155
Webcast:	http://public.viavid.com/index.php?id=144607

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts: 
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will BrainsWay report its financial results?

BrainsWay will report its first quarter 2021 financial results on May 20, 2021.

What time is the BrainsWay conference call?

The conference call is scheduled for 8:30 AM Eastern Time on May 20, 2021.

How can I access the BrainsWay conference call?

You can access the BrainsWay conference call by dialing 877-407-3982 for the U.S. or via the webcast at their investor relations website.

What are the FDA-cleared indications for BrainsWay's treatment?

BrainsWay's FDA-cleared indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction.